In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention
Viruses · 15.05.2026 · 18 (5) · 561
DOI: 10.3390/v18050561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 15.05.2026. Verfasst von Ruohui Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
MK-2048 is a potent second-generation HIV integrase inhibitor that has demonstrated acceptable safety and pharmacokinetics (PKs) in clinical trials of vaginal formulations. The substrate-type interactions between MK-2048 and the transporters/metabolizing enzymes that are highly expressed in the human female reproductive tract (FRT) were evaluated. The interactions between MK-2048 and P-gp/BCRP were investigated using a cellular bidirectional permeability assay, while those between MK-2048 and MRP4 were assessed using a vesicular uptake assay. Reaction phenotyping was performed to characterize the interactions between MK-2048 and CYP1A1 and CYP1B1. Using human cervicovaginal fluids (CVFs), MK-2048’s solubility was determined using a thermodynamic solubility method and its protein binding was determined using a rapid equilibrium dialysis method. Our study shows an efflux of MK-2048 in P-gp/BCRP-overexpressing MDCKII cells, which was reduced by a P-gp/BCRP inhibitor. Uptake of MK-2048 in MRP4/control vesicles was found to be ATP-independent. MK-2048 was metabolized by the CYP1A1 enzyme but not by CYP1B1. These data confirm that MK-2048 is a substrate of P-gp, BCRP, and CYP1A1, but is not a substrate of MRP4 or CYP1B1. MK-2048 displays low solubility and high protein binding in human CVF. This data suggests that MK-2048 may potentially interact with drugs that modulate the activity of P-gp, BCRP, and CYP1A1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Magee-Womens Research Institute, Pittsburgh, PA 15213, USA.
- Department of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
ORCID-Profile: Ruohui Zheng, Guru Raghavendra Valicherla, Junmei Zhang
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Zheng, R., Valicherla, G. R., Graebing, P. W., Zhang, J., Hillier, S. L., & Rohan, L. C. (2026). In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention. Viruses, 18(5), 561. https://doi.org/10.3390/v18050561
Vancouver
Zheng R, Valicherla GR, Graebing PW, Zhang J, Hillier SL, Rohan LC. In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention. Viruses. 2026;18(5):561. doi:10.3390/v18050561
BibTeX
@article{Zheng2026,
author = {Zheng, Ruohui and Valicherla, Guru Raghavendra and Graebing, Phillip W and Zhang, Junmei and Hillier, Sharon L and Rohan, Lisa Cencia},
title = {In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention},
journal = {Viruses},
year = {2026},
volume = {18},
number = {5},
pages = {561},
doi = {10.3390/v18050561}
}
EUVIMED